San Diego’s Genomatica, a Pioneer in Industrial Biotechnology, Files for IPO

San Diego-based Genomatica, an industrial biotech that uses engineered microorganisms to produce high-value chemicals in fermentation tanks, has submitted plans for an initial public offering, according to a regulatory filing today. The underwriters include Morgan Stanley, J.P. Morgan Securities, and Jefferies & Company, and the company hopes to someday trade under the ticker symbol GENO.

All shares to be sold in the IPO will be offered by Genomatica. The company did not specify the number of shares to be offered, or the price range, but CEO Christophe Schilling indicated in June that Genomatica was looking to raise about $150 million.

The San Diego company, which was founded in 1998, has emerged in recent years as a pioneer in industrial biotechnology. Using a proprietary software technology to model metabolic processes, the company has successfully demonstrated its ability to create a blueprint for genetically engineering microorganisms such as E. coli bacteria to consume renewable resources (sugars) and produce butanediol, or BDO—and more recently—butadiene. Before now, such chemicals were produced by the petrochemical industry, using methane and other fossil fuels as the raw material in CO2-spewing processes.

BDO is used to make a resilient plastic material, which in turn is the raw material for making spandex clothing, running shoes, and dashboards, among other things. In its IPO filing, Genomatica says global demand for BDO in 2009 was 2.8 billion pounds, which equates to a market size of approximately $4 billion (based on prices in June 2011). The company estimates that the global market for butadiene, a basic chemical used in a variety of other everyday products such as tires, carpeting and latex products, is even bigger—about 20 billion pounds and $40 billion. The company says it has identified about 20 other intermediate chemical products for its future product pipeline.

Because of the industrial-scale production required, Genomatica has been forging partnerships with industry partners, such as Tate & Lyle in the United States and Novamont in Europe.

Genomatica was founded in 1998, and operated as a research and development group with specialized expertise in using its proprietary software technology to model metabolic processes. The company funded its operations mostly through collaborative research agreements, grants, and by licensing its software to other researchers. In 2007, the company seemed to re-invent itself—or at least to focus more directly on its current commercialization strategy.

The company says it has raised $84.2 million in total proceeds from the issuance of convertible preferred stock. It’s biggest existing shareholders include Fort Worth, TX-based TPG Biotechnology Partners, which holds 19.1 percent; Menlo Park, CA-based Mohr Davidow Ventures, 17.3 percent; San Bruno, CA-based VantagePoint Venture Partners, 12.6 percent; Palo Alto, CA-based Alloy Ventures, 10.4 percent; and Batios Holdings of the British Virgin Islands, 7.4 percent.

Bruce V. Bigelow was the editor of Xconomy San Diego from 2008 to 2018. Read more about his life and work here. Follow @bvbigelow

Trending on Xconomy

By posting a comment, you agree to our terms and conditions.

3 responses to “San Diego’s Genomatica, a Pioneer in Industrial Biotechnology, Files for IPO”

  1. Jerry Jeff says:

    As someone who works in the bio-based chemicals field, my impression has been that Genomatica’s software tools are the best out there. But even with that advantage it has taken them 13 years so far and they are still at pilot or demo scale for their first product. Obviously I wish them the best of luck and success, but the lesson is clear: biology is slow and hard.

  2. Good insight Jerry. Thanks. The part I wonder about is whether Genomatica started in 1998 knowing they would focus on sustainable chemicals a decade later.